Cargando…

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the onl...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLornan, Donal P., Yakoub-Agha, Ibrahim, Robin, Marie, Chalandon, Yves, Harrison, Claire N., Kroger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442950/ https://www.ncbi.nlm.nih.gov/pubmed/30872371 http://dx.doi.org/10.3324/haematol.2018.206151

Ejemplares similares

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
por: Tamari, Roni, et al.
Publicado: (2023)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
por: Bacigalupo, Andrea, et al.
Publicado: (2021)

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
por: Polverelli, Nicola, et al.
Publicado: (2022)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2016)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Graft-versus-host disease in allogeneic transplantation: the good and the bad
por: Kröger, Nicolaus-Martin
Publicado: (2022)

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2019)

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
por: Sora, Federica, et al.
Publicado: (2022)

Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation
por: Chiusolo, Patrizia, et al.
Publicado: (2022)

Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study
por: Choudhary, Dharma, et al.
Publicado: (2023)

Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
por: Beauvais, David, et al.
Publicado: (2022)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ivrsstqc52shb4t8it6cngouqu